

## Kaiser Permanente

### COVID-19 Vaccine FAQ – Updated November 30, 2021

#### Contracted and Non-Contracted Providers

The Coronavirus Aid, Relief, and Economic Security (CARES) Act requires that group health plans and health insurance issuers of group and individual coverage subject to the ACA's preventive service mandate cover any new FDA approved coronavirus vaccine, without member cost sharing, fifteen (15) days after each is recommended by the Advisory Committee on Immunization Practices (ACIP).

The purpose of these FAQs is to communicate to Kaiser Permanente (KP) contracted and non-contracted providers how to submit claims for reimbursement of COVID-19 vaccine administration. These FAQs reflect the requirements of the interim final rule (federal regulation) regarding vaccine administration as well as other information.

#### **1. What is the cost share for the COVID-19 vaccine and administration?**

Federal regulation provides that, for the duration of the federal Public Health Emergency, the cost share must be zero dollars (\$0.00) for the vaccine and/or its administration, and that the vaccine and/or its administration is not subject to the health plan's deductible, if any. The Public Health Emergency declared by former HHS Secretary Azar early last year has been extended.

A cost share for the office visit may be charged if vaccine administration is NOT the sole purpose of the encounter.

#### **2. Must contracted and non-contracted providers obtain preauthorization from KP to administer a COVID-19 vaccine?**

No prior authorization from KP is required to administer the COVID-19 vaccine as mandated by the CARES Act.

#### **3. Can KP members obtain a COVID-19 vaccine from a contracted or non-contracted provider?**

Yes, during the Public Health Emergency, KP members may obtain a COVID-19 vaccine from a contracted or non-contracted provider. Providers must have entered into a CDC COVID-19 Vaccination Program Provider Agreement to administer the COVID-19 vaccine.

#### **4. Are providers allowed to bill KP for the COVID-19 vaccine?**

Providers who receive vaccine dosages from the Federal government at no charge through the Operation Warp Speed (OWS) distribution may not bill for the vaccine. OWS supply is not expected to be exhausted for several months. When providers must procure vaccines at a cost, the process for administration and billing of vaccines will be updated accordingly.

For Medicare, effective date of service, January 1, 2022, the COVID-19 vaccine and administration (including approved booster doses), will be reimbursed via Medicare Advantage under Medicare Part B, without cost sharing. Providers should bill KP via EDI for the COVID-19 vaccine. For more information about COVID-19 vaccine policies and guidance, please see the toolkits found at <https://www.cms.gov/COVIDvax>.

## **5. How do providers get reimbursed for COVID-19 vaccine administration?**

### **Medicare**

Effective for dates of service prior to January 1, 2022, for vaccine administration to KP Medicare members, providers must submit a Medicare fee-for-service claim to CMS.

Effective date of service, January 1, 2022, the COVID-19 vaccine and administration (including approved booster doses), will be reimbursed via Medicare Advantage under Medicare Part B, without cost sharing. Providers should no longer bill CMS directly for COVID-19 vaccine administration. Providers should bill KP via EDI for vaccine administration.

For more information about COVID-19 vaccine policies and guidance, please see the toolkits found at <https://www.cms.gov/COVIDvax> and <https://www.cms.gov/medicare/covid-19/medicare-billing-covid-19-vaccine-shot-administration>

### **MediCal/Medicaid**

For vaccine administration to KP Medi-Cal members (CA only), providers must submit a claim to DHCS for reimbursement. For vaccine administration to KP Medicaid or CHP members (CO, HI, VA, MD, OR, WA), providers should bill KP via EDI for vaccine administration.

### **Commercial**

Providers should bill KP via EDI for vaccine administration for KP commercial (non-Medicare, non-Medicaid) members.

## **6. What is the KP reimbursement rate for COVID-19 vaccine administration to commercial members?**

KP will not reimburse providers for the vaccine, if providers are obtaining it from the federal government which is purchasing and distributing it. KP will reimburse for vaccine administration based on the applicable Medicare rate for all fully insured (including grandfathered plan) commercial HMO, Kaiser Permanente Insurance Company (KPIC) and self-funded plan members. In-network and out-of-network providers will be reimbursed at the applicable Medicare rate for the location in which administration occurred on the date on which the vaccine is administered.

7. What codes should be submitted to KP for COVID-19 vaccine administration reimbursement?

## COVID-19 VACCINATIONS

Vaccine Administration No additional qualifiers needed	
Table 8	
<b>0001A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose <b>(Pfizer)</b>
<b>0002A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose <b>(Pfizer)</b>
<b>0003A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose. <b>(Pfizer)</b>
<b>0004A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose <b>(Pfizer)</b>
<b>0011A</b>	Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose <b>(Moderna)</b>
<b>0012A</b>	Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose <b>(Moderna)</b>
<b>0013A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose <b>(Moderna)</b>
<b>0021A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage; first dose <b>(AstraZeneca)</b>
<b>0022A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage; second dose <b>(AstraZeneca)</b>

<b>0031A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage, single dose ( <b>Janssen</b> )
<b>0034A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5 mL dosage; booster dose (Janssen)
<b>0041A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose ( <b>Novavax</b> )
<b>0042A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose ( <b>Novavax</b> )
<b>0051A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose ( <b>Pfizer</b> )
<b>0052A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose ( <b>Pfizer</b> )
<b>0053A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose ( <b>Pfizer</b> )
<b>0054A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose ( <b>Pfizer</b> )
<b>0064A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose ( <b>Moderna</b> )
<b>0071A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose (Pfizer - PEDS)
<b>0072A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose (Pfizer - PEDS)
<b>D1701</b>	SARSCOV2 COVID-19 VAC Administration mRNA 30mcg/0.3mL IM DOSE 1 ( <b>Pfizer</b> ) Effective 3/15/2021

<b>D1702</b>	SARSCOV2 COVID-19 VAC Administration mRNA 30mcg/0.3mL IM DOSE 2 <b>(Pfizer) Effective 3/15/2021</b>
<b>D1703</b>	SARSCOV2 COVID-19 VAC Administration mRNA 100mcg/0.5mL IM DOSE 1 <b>(Moderna) Effective 3/15/2021</b>
<b>D1704</b>	SARSCOV2 COVID-19 VAC Administration mRNA 100mcg/0.5mL IM DOSE 2 <b>(Moderna) Effective 3/15/2021</b>
<b>D1705</b>	SARSCOV2 COVID-19 VAC Administration rS-ChAdOx1 5x1010 VP/.5mL IM DOSE 1 <b>(AstraZeneca) Effective 3/15/2021</b>
<b>D1706</b>	SARSCOV2 COVID-19 VAC Administration rS-ChAdOx1 5x1010 VP/.5mL IM DOSE 2 <b>(AstraZeneca) Effective 3/15/2021</b>
<b>D1707</b>	SARSCOV2 COVID-19 VAC Administration Ad26 5x1010 VP/.5mL IM SINGLE DOSE <b>(Janseen) Effective 3/15/2021</b>
<b>M0201</b>	COVID-19 vaccine administration inside a patient's home; reported only once per individual home, per date of service, when only COVID-19 vaccine administration is performed at the patient's home <b>(Medicare Only - Effective 6/8/2021)</b>

<b>COVID-19 Vaccine</b> <b>No additional qualifiers needed</b> <b><u>When COVID-19 doses for vaccine are provided by the government</u></b> <b><u>without charge, only bill for the administration. Don't include the drug codes on the claim.</u></b>	
Table 9	
<b>91300</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use <b>(Pfizer)</b>
<b>91301</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use <b>(Moderna)</b>
<b>91302</b>	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use <b>(AstraZeneca)</b>
<b>91303</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010. viral particles/0.5mL dosage, for intramuscular use <b>(Johnson &amp; Johnson)</b>
<b>91304</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use <b>(Novavax)</b>
<b>91305</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use <b>(Pfizer)</b>
<b>91306</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use <b>(Moderna)</b>

**91307**

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, trissucrose formulation, for intramuscular use (Pfizer - PEDS)